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Many clinicians with different training and practice are involved in the care of persons with dementia.
Whereas neurologists and psychiatrists focus their attention on the early phase of dementia, geriatricians and
palliative care specialists are particularly involved at the end of demented patients’ lives. To summarize the
progress of knowledge in this field, it seems possible to answer four fundamental questions.
When? Several longitudinal studies of cohorts of demented and nondemented patients showed clearly that de-
mentia is a risk factor for early death. There are no survival differences between Alzheimer’s and Lewy body dis-
ease patients. Patients with vascular dementia have the worst prognosis. These results need to be analyzed with
consideration of associated comorbidity, types and intensity of care, and dementia treatment.
Why? Studies conducted on the basis of death certificates appear to be biased. A large autopsy study per-
formed in the geriatric department of Geneva University Hospital showed no difference existed in immediate
causes of death between demented and nondemented hospitalized old patients. On the other hand, cardiac causes
are significantly more frequent in vascular dementia than in Alzheimer’s disease or mixed dementia patients.
How? Deaths of demented patients raise a lot of ethical considerations. It is always difficult to know demented
patients’ awareness of the end of life. It is really difficult to accompany these patients, with whom communication
is essentially nonverbal. During this delicate phase of the end of life, how can formal health professionals help the
family members who are afraid of both death and dementia?
And after? Suffering of family members and caregivers has to be strongly considered. This goal includes the
improvement of our communication skills with the patient, and the facilitation of interdisciplinary exchanges
with the caregiver’s team and with the family members to allow acceptance of the death.
 
EMENTIA is certainly one of the most dramatic
medical and economic challenges that our society
will face in the coming years” (1). If the specificity of care
appears incontestable at the early stages of the disease
(959,000 new cases of dementia per year in the United States
in 1994—ninth most frequent disease in incidence) (2), the
care at the end of life of the 7,082,000 existing demented pa-
tients (eighth most prevalent disease in the United States) (2)
has to be better considered, provided, and studied. Geriatri-
cians and palliative care specialists are particularly con-
cerned because, for each decade after the sixth, the number
of affected people doubles, so that an estimated 30% of the
85
 

 
 population is affected by Alzheimer’s disease (AD)
(3,4). The end-of-life care of demented patients needs to
reach the best possible quality. Its intensity has to be appro-
priate, timely, and ethically adapted, considering the multi-
ple circumstances, the family concern, and the different en-
vironmental conditions (living at home or in an institution).
To highlight the importance of the end-of-life care of de-
mented patients, we will consider the survival of demented ver-
sus nondemented patients and the causes of death of patients
with or without dementia, before examining specific ethical is-
sues of the end of life involved in the care of cognitively dis-
turbed patients. A discussion of the suffering of family mem-
bers and caregivers will conclude this literature review.
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A 5-year follow-up of Canadians older than 65 years liv-
ing in the community (2923 with and 7340 without demen-
tia) showed that elderly people with dementia have clearly
increased mortality rates compared to elderly people with-
out cognitive impairment in all age/gender categories (5).
Three-year and 5-year mortality risk of demented patients
living in the community reached 45% to 48% (6,7), and 70%
(8), respectively. Median length of life from diagnosis was
reported to be 5.3 years (9) and 5.4 years (10) in two pro-
spective studies. But the median survival after onset of de-
mentia (and not time of study entry) appears shorter, after
adjustment for length bias, than previously stressed: 3.3
years (95% confidence interval [CI] 2.7–4) (11). A 3-year
follow-up of 5362 community-dwelling Italian people be-
tween the ages of 65 and 84 years confirmed that the rela-
tive risk of dying (Cox proportional hazards model) for de-
mented patients was higher (risk ratio [RR] 
 

 
 3.61 [CI
2.55–5.11]) than for a patient with cancer (RR 
 

 
 2.01 [CI
1.20–3.38]), heart failure (RR 
 

 
 1.87 [CI 1.27–2.76]), or di-
abetes (RR 
 

 
 1.62 [CI 1.12–2.34]) (12). In the same study,
institutionalization appeared to be more dangerous (RR 
 

 
4.17 [CI 2.20–7.94]) than any pathological process consid-
ered separately (including dementia—see above). That is to
say, demented patients who are frequently institutionalized
at the advanced stage of the disease are really at the highest
risk of death (12). This relative risk is twice as high for men
compared to women (8,12) and increases with age, severity
of dementia, and its disability consequences (7,13). The de-
mentia etiology is also important to consider. Vascular de-
mentia (VAD) has a higher 5-year risk of mortality than AD
(8), while Lewy body disease has the same 3-year mortality
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risk as AD, considering the age at onset and the age at death
(14). But the number and the importance of associated dis-
eases were not known in this study and could have ex-
plained these findings, particularly the worst survival prog-
nosis of patients with VAD.
Moreover, independent of the medical conditions, the
types of social care seem to affect the survival of de-
mented patients. Participation at a day center as well as the
active support of family members appear to significantly
decrease the mortality risk, whereas the benefit of Meals
on Wheels on survival is not at all proved (6). This raises
the question of whether individual emotional support of
demented patients is more important than the type and
quantity of care?
Another interesting debate relates to the impact of the
new cholinesterase inhibitors on the survival of demented
patients. The safety of this category of drugs was demon-
strated on a total of 208 demented patients treated with
tacrine (15). Treatment with tacrine, at least at doses more
than 80 mg/d, appeared to be associated with a reduced like-
lihood of nursing home placement (16). This tendency is
supported by the results of a cost analysis based on a deci-
sion-analytic model constructed on the milestones in the
progression of AD (17). These various analyses suggested a
trend for lower mortality for patients receiving more than
120 mg/d of tacrine (16,17). This tendency was confirmed
by a recent retrospective cohort study of 1449 users of
tacrine compared with 6119 nonusers matched on facility,
date of tacrine use, level of cognitive function, and demen-
tia diagnosis (18). The survival hazard rate ratio (HRR) was
0.76 (95% CI 
 

 
 0.70–0.83) for the users of tacrine, and
those who used higher doses (
 

 
80 mg/d) experienced the
greatest survival advantage (HRR 
 

 
 0.74; 95% CI 
 

 
 0.56–
1.0) (18). These data on increased survival of AD patients
treated with tacrine require us to reconsider the negative im-
pact of institutionalization (see above [12]) and raise the
same debate with the other cholinesterase inhibitor drugs
(19). Moreover, the economic impact of such treatments
needs to be reevaluated.
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At the end stage of the disease, persons with dementia are
often bedridden and are vulnerable to developing other
medical conditions and dying earlier than if they were not
demented (20). This is consistent with several studies re-
porting that the main causes of death of demented patients
are pneumonia and cardiovascular disease (21–24). Bron-
chopneumonia occurred in severely impaired patients more
often with AD (70.9%) than with VAD (25). Heart disease
and stroke predominated in the less cognitively impaired
patients with VAD (23). However, the above data were
almost exclusively based on death certificate reports,
which may not be sufficiently reliable. Morbidity and mor-
tality statistics arising from death certificates are seriously
flawed, because of the omission of important information
(26). In practice, deciding which disorders should be in-
cluded on death certificates reflects the opinion of the doc-
tor completing the form, and very often underlying causes
of death are not mentioned (26). This can explain why com-
parison of data from death certificates completed by either
attending physicians or by doctor-coroners and necropsy re-
ports shows large deviations in causes of death ranging
from 
 

 
91.6% to 
 

 
74.8% (27). The Canadian Study of
Health and Ageing proves that the sensitivity of the death
certificate and the question regarding diagnosis of dementia
was low (33% and 44%), although their specificity was very
high (93%) (28). Similar discrepancies have also been re-
ported by others, resulting in increased interest in geriatric
autopsy studies (29,30). Pathological series are scarce in the
literature. An autopsy series based on 72 cases showed that
pneumonia was the immediate cause of death in 72% of
clinically demented patients, while cardiovascular diseases
represented only 24% of the causes of death (31). Another
complete autopsy study performed on 120 hospitalized de-
mented VAD (
 
n
 
 
 

 
 34), mixed dementia (MD; 
 
n
 
 
 

 
 65), and
AD (
 
n
 
 
 

 
 21) neuropathologically confirmed and 222 non-
demented elders (mean age 84.9 
 

 
 6.9 years) showed that
the number of reported causes of death per patient was 1.7
in both groups (32). Among the reported causes of death in
each patient group, bronchopneumonia was identified as
the main immediate cause of death in 40.8% of demented
and 34.2% of nondemented patients. Infections of various
origins, including pulmonary tract infections, represented
53.3% and 48.6% of the causes of death in demented and
nondemented patients, respectively. The combination of
cardio- and cerebrovascular diseases (cardiac failure 
 

 
 pul-
monary embolism 
 

 
 myocardial infarction 
 

 
 central ner-
vous system hemorrhage) corresponded to 68.2% and
73.7% of the identified immediate causes of death in de-
mented and nondemented patients, respectively. No differ-
ence in infectious causes was observed between the various
dementia types, although the combined cardio- and cere-
brovascular causes of death were significantly more fre-
quent in VAD (91.0%) than in MD (61.3%) and AD
(52.1%) cases (
 
p
 
 
 

 
 .001). The major differences were in the
rate of cardiac failure in these various pathological cases:
VAD (44.1%), AD (19%), and MD (15.3%) (32).
In opposition with current opinion (33), this study (32)
strongly suggested, as have many others (29,34–36), that
dementia can only be considered as an underlying cause of
death. Moreover, demented patients died from the same
causes as nondemented hospitalized subjects, when quality
of care was not influenced by the cognitive status.
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Dementia is associated with a wide variety of underlying
conditions: poor nutrition resulting from diminishing intake
of fluids and liquids, urinary incontinence, skin breakdown,
and various types of infections that accelerate the progres-
sion of the common age-associated diseases (diabetes,
chronic heart failure, hip fracture) and precipitate the de-
mented patient into functional dependency (37). Although
the end-of-life issues are similar in demented and nonde-
mented patients (see above), the intensity and types of care
are really different in these two patient groups. A 13-month
retrospective study compared the hospital charts of two
kinds of end-of-life patients: demented (
 
n
 
 
 

 
 80) and meta-
static cancer patients (
 
n
 
 
 

 
 84) (38). Complex invasive or
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noninvasive diagnostic tests were significantly more fre-
quently used in cancer than in demented patients (respec-
tively, 41% vs 13%—
 
p
 
 
 

 
 .002 and 49% vs 23%—
 
p
 
 
 

 
 .02),
while enteral tube feeding and antibiotics for an identifiable
infection were significantly less often prescribed in cancer
than in demented patients (respectively, 9% vs 26%—
 
p
 
 
 

 
.02 and 45% vs 65%—
 
p
 
 
 

 
 .004) (38). Cardiopulmonary re-
suscitation was practiced with the same frequency in the
two different groups of patients (38). These disturbing find-
ings raise the difficult issues of appropriate quality of care
at the terminal stage for demented patients.
Some of the most troublesome complications of advanced
dementia, and particularly during the terminal phase of de-
mentia, are the behavioral symptoms: physical aggression
and delusions, wandering, agitation, sleep problems, and
anxiety are among the most important (39). “Behavioral and
psychological symptoms of dementia” (BPSD) is a recently
coined term to describe this heterogeneous range of noncog-
nitive symptoms occurring in people with dementia of any
etiology (40). They result in emotional suffering for patients
and caregivers, excess disability and mortality, premature in-
stitutionalization, and increased financial cost (40). Antipsy-
chotic neuroleptics are the most commonly used medications
for the treatment of psychotic symptoms in AD. Although
a vast arsenal of antipsychotics and antidepressants is
available to treat behavioral symptoms of AD, none of
these drugs has been approved specifically for this purpose.
Nonetheless, physicians prescribe such medications without
proper labelling and despite a dearth of published controlled
studies supporting this use. A meta-analysis of the available
placebo-controlled trials by Schneider and colleagues in
1990 (41) found that the use of these drugs produced only a
modest effect and that no single antipsychotic medication
had greater efficacy than another. However, more recent
data have shown a significant effect of atypical antipsychot-
ics in reducing behavioral disturbances (42,43). Side effect
profiles and comorbidities must also be considered when
prescribing these drugs. Several studies have shown that
cholinesterase inhibitors also reduce behavioral and psycho-
logical symptoms including agitation, apathy, anxiety, pac-
ing, and visual hallucinations (9,10). Nonpharmacological
intervention is also an important part of dementia care. Few
controlled trials have been published on the effectiveness of
various nonpharmacological strategies (44–46).
Frequently, BPSD is the atypical clinical presentation of
pain and suffering (47). Assessment of discomfort in 104
late-stage demented patients (mean age 85 years) with the
Assessment of Discomfort in Dementia scales showed that
the most frequently displayed behaviors were tense body lan-
guage, sad facial expression, persevering verbalizations, and
verbal outbursts (47). These nonverbal cues and subjective
states are very difficult to identify. A French study stressed
this point by comparing the estimation of pain recognition
and adequate treatment in hospitalized late-stage demented
patients: Physicians thought they recognized pain in 96%
of the cases, assistant nurses estimated that it was true
only in 68%, and nurses were even more severe, thinking
that pain was not recognized and not adequately treated in
44% of the cases (48). Moreover, the same study shows that
physicians estimated that the care decision was really the re-
sult of an interdisciplinary consensus in 87% of the cases,
while, respectively, assistant nurses and nurses thought that
this was the case in only 55% and 51% of the cases (48).
These differences attest to the inability of the caregivers to
identify pain and suffering in advanced dementia patients.
The main consequence is the tendency to undermedicate
pain in these patients (49,50). This has led to the stressing of
pain as the fifth vital sign with the hope that this will in-
crease awareness of inadequately treated pain in older per-
sons (51). Unfortunately, instead of providing pain control
and spiritual support during the dying process, there is a ten-
dency in the medical system to concentrate on life-prolong-
ing interventions (52). Four main medical interventions are
considered as life-prolonging interventions and are indeed
raising ethical debates: cardiopulmonary resuscitation, renal
dialysis, tube feeding, and antibiotic prescription. At the ad-
vanced stage of dementia, only enteral nutrition and antibi-
otic use raise an ethical debate.
A review of evidence of the usefulness of tube feeding in
patients with advanced dementia including all Medline peer-
reviewed papers published between 1996 and 1999 found
that tube feeding does not clinically improve important out-
comes such as survival, functioning, risk of pressure sores,
risk of infection, or risk of aspiration (53). However, it must
be recognized that malnutrition and vitamin deficiencies
may worsen dementia in some persons (54).
Infectious complications are very common causes of
death in demented patients (32). The atypical clinical pre-
sentations of infection are frequent, and when the infection
is recognized, antibiotic use needs to be discussed and inte-
grated into the comprehensive assessment of the patient
(physiological reserves, severity of dementia). Sometimes,
the patient’s discomfort is linked to an evident clinical in-
fection, particularly a pulmonary tract infection. In this
case, the antibiotic prescription is useful, whatever the de-
mentia stage, but the antibiotic choice has to be accurate,
adequate, and timely (55,56).
The anguish of end of life seen in all patients exists also
in severely demented patients. The quality of terminal care
of these patients is greatly dependent on the patient’s aware-
ness, which is very often fluctuating. Sometimes, the patient
is confused and unaware of his or her condition; at other
times, the patient knows that he or she is dying and attempts
to communicate (57). What is the significance of this at-
tempt? Is there any nonverbal hidden message? Is there any
expression of a wish to die? Too often, these questions re-
main without valuable responses. This raises important and
difficult ethical debates within the caregiver staff and with
the family members who are always completely disap-
pointed by the fluctuating mental status. The ethical con-
cerns about palliative drug treatment of these demented
patients can be reduced but never completely solved. Ad-
vanced health directive planning is probably the best mech-
anism for respecting the demented patient’s prior self-deter-
mination (58). The role of euthanasia as practiced in
Holland and Oregon is beyond the scope of this review.
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Confronted with the terminal stage of life of a demented
patient, family members and health care professionals face
 END-OF-LIFE CARE
 
M643
 
two important fears: the fear of death and the fear of demen-
tia (59). The mourning process itself is influenced by vari-
ous factors, such as the symbolic role of the dying person,
the unfulfilled requests, the death circumstances, and the
quality of the last moments of life (60). In the case of death
of a demented patient, the mourning process is different.
The loss, the separation from a loved one who has been de-
mented for several years, is even more difficult. The antici-
pation of the death, which was preceded by a social death,
does not help the mourning process (60).
Thus, in the terminal phase of life of demented patients, it
is important to try improving communication skills with the
patient to facilitate interdisciplinary exchanges, to help fam-
ily members, to clarify the inescapable fatal outcome of
their loved one, and to better cope with their suffering. After
the death, it is fundamental to support the family during the
mourning process, which, in these cases, is always difficult.
Often, mourning can lead to severe depression in family
members (60).
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